Favorable safety outcomes may be attributed to the novel mechanism of action of asciminib specific to ABL kinases and may provide an advantage over key comparators in ≥ 3L CP-CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.